Aptamer Diagnostic Kits Global Market Report 2026

The aptamer diagnostic kits market size has grown rapidly in recent years. It will grow from $1.85 billion in 2025 to $2.16 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, rising demand for sensitive diagnostic tools, growth in hospital and laboratory infrastructure, adoption of enzyme-linked and colorimetric kits, technological advances in aptamer synthesis.

The aptamer diagnostic kits market size is expected to see rapid growth in the next few years. It will grow to $3.97 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to growing use of RNA and peptide aptamer kits, increasing integration with AI-based diagnostic analytics, rising demand for personalized medicine applications, expansion of point-of-care and rapid diagnostic testing, growing adoption in cancer and cardiovascular disease diagnosis. Major trends in the forecast period include increasing adoption of high-sensitivity aptamer kits, rising demand for multiplex diagnostic capabilities, growing integration of fluorescence and electrochemical technologies, expansion of infectious disease diagnostic applications, rising focus on rapid point-of-care testing.

The rising incidence of infectious diseases is anticipated to drive the expansion of the aptamer diagnostic kits market in the coming years. Infectious diseases are medical conditions caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, that can be transmitted from one individual, animal, or environment to another. Infectious diseases are health conditions resulting from pathogenic microorganisms, such as bacteria, viruses, fungi, and parasites, that can spread among people, animals, or through environmental exposure. Aptamer diagnostic kits assist in the management of infectious diseases by facilitating rapid, highly sensitive, and specific identification of pathogens or disease biomarkers in patient samples, enabling early diagnosis, prompt treatment, and enhanced disease monitoring and control. For example, in March 2024, as reported by the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Consequently, the growing incidence of infectious diseases is fueling the expansion of the aptamer diagnostic kits market.

The rise in healthcare investments is expected to accelerate the growth of the aptamer diagnostic kits market in the foreseeable future. Healthcare investments refer to the distribution of financial resources by governments, institutions, or private organizations to strengthen medical infrastructure, services, technologies, and accessibility to healthcare. Healthcare investments are increasing as governments and institutions allocate greater funding to reinforce medical infrastructure, broaden access to healthcare services, and encourage the adoption of advanced medical technologies. Investments in healthcare facilitate the development and implementation of aptamer-based diagnostic kits, supporting quicker, more accurate, and cost-efficient disease detection while enhancing patient outcomes. For instance, in January 2026, according to the Centers for Medicare & Medicaid Services, a US-based government agency, national health expenditure (NHE) is forecasted to grow at an average annual rate of 5.8% from 2024 to 2033, surpassing the projected average gross domestic product (GDP) growth of 4.3% and increasing the share of health spending in GDP from 17.6% in 2023 to 20.3% by 2033. Therefore, the growth in healthcare investments is propelling the expansion of the aptamer diagnostic kits market.

In May 2025, Aptamer Sciences Co. Ltd., a South Korea-based biotechnology company that focuses on delivering aptamer-based diagnostic products and kits, entered into a partnership with Apidi Healthcare Pvt. Ltd. to launch a lung cancer diagnostic kit in India. Through this collaboration, Aptamer Sciences Co., Ltd. and Apidi Healthcare Pvt. Ltd. seek to broaden access to early and precise lung cancer detection, utilize advanced aptamer-based biomarker technology, and enhance diagnostic outcomes for patients. Apidi Healthcare Pvt. Ltd. is an India-based manufacturing company that specializes in diagnostic solutions and healthcare services.

Major companies operating in the aptamer diagnostic kits market are Kaneka Corporation, Maravai LifeSciences, Nexus Dx Inc, Creative Biolabs, Aptitude Medical Systems Inc, Aptamer Group Limited, Base Pair Biotechnologies Inc, Aptamer Sciences Inc, Aptagen LLC, Vivonics Inc, AptaMatrix Inc, Aptus Biosciences, AuramerBio Ltd, Neoncorte Bio, Bio‑Connect B.V, Aptarion Biotech AG, SB Bioscience Co. Ltd, NeoVentures Biotechnology Inc, AM Biotechnologies LLC, NeoVentures Biotechnology Inc.

North America was the largest region in the aptamer diagnostic kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aptamer diagnostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aptamer diagnostic kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aptamer diagnostic kits market consists of sales of next generation ligand kits, multiplexed detection assay kits, and custom aptamer assay development kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Aptamer diagnostic kits are analytical tools that utilize synthetic single-stranded DNA or RNA molecules, known as aptamers, which can specifically bind to target molecules with high affinity. They detect biomolecules, pathogens, or chemical compounds by producing measurable signals upon binding. These kits provide rapid, sensitive, and selective diagnostic capabilities for various medical, environmental, and research applications.

The key product types of aptamer diagnostic kits include deoxyribonucleic acid (DNA) aptamer kits, ribonucleic acid (RNA) aptamer kits, and peptide aptamer kits. DNA aptamer kits use synthetic deoxyribonucleic acid sequences to selectively bind target molecules for precise and rapid diagnostics. These solutions are available with electrochemical, optical, colorimetric, fluorescent, and other technologies. Applications include infectious disease diagnosis, cancer diagnosis, cardiovascular disease diagnosis, neurological disorders, and other areas, serving end users such as hospitals and clinics, diagnostic laboratories, research institutes, and other end-users.

Tariffs on imported reagents, aptamer synthesis kits, and analytical instruments are affecting the aptamer diagnostic kit market by increasing procurement and manufacturing costs, particularly impacting RNA and peptide aptamer kit segments. Regions such as North America, Europe, and Asia-Pacific that rely heavily on imported materials are most affected. While tariffs raise overall costs, they encourage local production, stimulate regional R&D in diagnostic technologies, and foster development of cost-efficient, high-accuracy kits, offering potential long-term benefits to market resilience.

The aptamer diagnostic kits market research report is one of a series of new reports that provides aptamer diagnostic kits market statistics, including aptamer diagnostic kits industry global market size, regional shares, competitors with a aptamer diagnostic kits market share, detailed aptamer diagnostic kits market segments, market trends and opportunities, and any further data you may need to thrive in the aptamer diagnostic kits industry. This aptamer diagnostic kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.